Olanzapine: A systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response

Journal of Clinical Psychopharmacology

Volumn 33, Issue 3, 2013, Pages 329-335

  Bishara, Delia ^a   Olofinjana, Olubanke ^a   Sparshatt, Anna ^a   Kapur, Shitij ^b   Taylor, David ^a,b   Patel, Maxine X ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

dopamine occupancy; olanzapine; plasma concentration; plasma level; psychotic disorders; therapeutic drug monitoring

Indexed keywords

DOPAMINE 2 RECEPTOR; OLANZAPINE;

ARTICLE; BIPOLAR DISORDER; CLINICAL EVALUATION; CORRELATIONAL STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG MONITORING; DRUG RECEPTOR BINDING; EFFECT SIZE; EMBASE; GENDER; HUMAN; MEDLINE; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; RECEPTORS, DOPAMINE D2; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 84877579225     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31828b28d5     Document Type: Article

References (41)

1. Lieberman JA, McEvoy JP, Swartz MS, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353: 1209-1223.
2. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008; 371: 1085-1097.
3. Kantrowitz JT, Citrome L. Olanzapine: review of safety 2008. Expert Opin Drug Saf. 2008; 7: 761-769.
4. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001; 62: 92-100.
5. Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008; 28: 392-400.
6. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011; 44: 195-235.
7. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999; 37: 177-193.
8. Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther. 1996; 276: 658-666.
9. Kassahun K, Mattiuz E, Nyhart E Jr, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos. 1997; 25: 81-93.
10. Walter SD, Yao X. Effect sizes can be calculated for studies reporting ranges for outcome variables in systematic reviews. J Clin Epidemiol. 2007; 60: 849-852.
11. Peuskens J, Mertens C, Geerts S, et al. Open study evaluating the onset of antipsychotic action of olanzapine in the treatment of patients with schizophrenia, schizophreniform or schizo-affective disorder. Int J Psychiatry Clin Pract. 2004; 8: 199-204.
12. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997; 7: 125-137.
13. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999; 156: 286-293.
14. Mamo D, Kapur S, Keshavan M, et al. D(2) receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology. 2008; 33: 298-304.
15. Esel E, Basturk M, Saffet GA, et al. Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients. Psychoneuroendocrinology. 2001; 26: 641-647.
16. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000; 157: 514-520.
17. Citrome L, Stauffer VL, Chen L, et al. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol. 2009; 29: 278-283.
18. Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res. 1999; 40: 101-104.
19. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol. 1997; 17: 472-477.
20. Attarbaschi T, Sacher J, Geiss-Granadia T, et al. Striatal D(2) receptor occupancy in bipolar patients treated with olanzapine. Eur Neuropsychopharmacol. 2007; 17: 102-107.
21. Catafau AM, Penengo MM, Nucci G, et al. Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. J Psychopharmacol. 2008; 22: 882-894.
22. Howes OD, Egerton A, Allan V, et al. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des. 2009; 15: 2550-2559.
23. Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007; 46: 359-388.
24. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry. 1998; 155: 921-928.
25. Perry PJ, Argo TR, Carnahan RM, et al. The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol. 2005; 25: 250-254.
26. Lindenmayer JP, Liu-Seifert H, Kulkarni PM, et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry. 2009; 70: 990-996.
27. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit. 2003; 25: 46-53.
28. Mauri MC, Steinhilber CP, Marino R, et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry. 2005; 20: 55-60.
29. Perry PJ, Lund BC, Sanger T, et al. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol. 2001; 21: 14-20.
30. Bergemann N, Frick A, Parzer P, et al. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry. 2004; 37: 63-68.
31. Eschweiler GW, Bartels M, Langle G, et al. Heart-rate variability (HRV) in the ECG trace of routine EEGs: fast monitoring for the anticholinergic effects of clozapine and olanzapine? Pharmacopsychiatry. 2002; 35: 96-100.
32. Linnet K, Olesen OV. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication. Ther Drug Monit. 2002; 24: 512-517.
33. Aichhorn W, Marksteiner J, Walch T, et al. Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. J Child Adolesc Psychopharmacol. 2007; 17: 665-674.
34. Weiss U, Marksteiner J, Kemmler G, et al. Effects of age and sex on olanzapine plasma concentrations. J Clin Psychopharmacol. 2005; 25: 570-574.
35. Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008; 48: 157-165.
36. Haslemo T, Eikeseth PH, Tanum L, et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol. 2006; 62: 1049-1053.
37. Patel MX, Bowskill S, Couchman L, et al. Plasma olanzapine in relation to prescribed dose and other factors. Data from a therapeutic drug monitoring service, 1999-2009. Psychopharmacology. 2011; 31: 1-7.
38. Robertson MD, McMullin MM. Olanzapine concentrations in clinical serum and postmortem blood specimensVwhen does therapeutic become toxic? J Forensic Sci. 2000; 45: 418-421.
39. Rao ML, Hiemke C, Grasmader K, et al. Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring. Fortschr Neurol Psychiatr. 2001; 69: 510-517.
40. Hiemke C, Dragicevic A, Grunder G, et al. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit. 2004; 26: 156-160.
41. Lin YC, Ellingrod VL, Bishop JR, et al. The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Ther Drug Monit. 2006; 28: 668-672.